This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hartmann, A. Articles by Knuechel, R. Search for Related Content PubMed PubMed Citation Articles by Hartmann, A. Articles by Knuechel, R.

Occurrence of Chromosome 9 and p53 Alterations in Multifocal Dysplasia and Carcinoma in Situ of Human Urinary Bladder¹

Institute of Pathology, University of Regensburg, 93042 Regensburg (A. Ha., G. S., F. H., R. K.), and Department of Urology, Ludwig Maximilian University, 81377 Munich (D. Z., E. H., A. Ho.), Germany

To define the genetic changes of flat urothelial lesions, carcinoma in situ (CIS) and moderate dysplasias (DII) were investigated for alterations in the two chromosomal regions most frequently involved in bladder cancer. Overall, 33 CIS and 16 DII from 21 patients were used to microdissect urothelium. Dual color fluorescence in situ hybridization (FISH) using gene locus probes of 9q22 (FACC), 9p21 (CDK), 17p13 (p53), and related centromeric probes was applied on interphase nuclei. In parallel, preamplified DNA of these samples was used for loss of heterozygosity (LOH) analyses with eight microsatellite markers on chromosomes 9p, 9q and 17p, and for sequencing of exons 5–9 of p53. Data indicated nearly identical deletion frequencies for chromosomes 9 and 17 for CIS (chromosome 9, 86%; p53, 84%). DII showed a lower deletion rate in comparison with CIS (chromosome 9, 75%; p53, 53%). A very high correlation between the results of FISH and LOH analyses was found. p53 mutations were detected in 12 of 15 patients (CIS, 72%; DII, 67%). In three of 16 patients with multifocal tumors, oligoclonal lesions were identified by LOH analyses, a finding further supported by sequencing of p53, by which two different p53 deletions were detected in two cases. In conclusion, data from microdissected flat urothelial lesions indicate that chromosome 9 deletions cannot be regarded as indicators of papillary growth, because they are found frequently in both types of flat lesions of the urothelium: those associated with papillary tumors and those that are not. The similar distribution and lower amount of genetic changes in DII render DII a possible precursor lesion of CIS.

This article has been cited by other articles:

				L. Knoops, R. Haas, S. de Kemp, D. Majoor, A. Broeks, E. Eldering, J. P. de Boer, M. Verheij, C. van Ostrom, A. de Vries, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma Blood, August 15, 2007; 110(4): 1116 - 1122. [Abstract] [Full Text] [PDF]

				S. Hernandez, E. Lopez-Knowles, J. Lloreta, M. Kogevinas, A. Amoros, A. Tardon, A. Carrato, C. Serra, N. Malats, and F. X. Real Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas J. Clin. Oncol., August 1, 2006; 24(22): 3664 - 3671. [Abstract] [Full Text] [PDF]

				T. D. Jones, M. Wang, J. N. Eble, G. T. MacLennan, A. Lopez-Beltran, S. Zhang, A. Cocco, and L. Cheng Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis Clin. Cancer Res., September 15, 2005; 11(18): 6512 - 6519. [Abstract] [Full Text] [PDF]

				S. Hernandez, E. Lopez-Knowles, J. Lloreta, M. Kogevinas, R. Jaramillo, A. Amoros, A. Tardon, R. Garcia-Closas, C. Serra, A. Carrato, et al. FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis Clin. Cancer Res., August 1, 2005; 11(15): 5444 - 5450. [Abstract] [Full Text] [PDF]

				R. Montironi and A. Lopez-Beltran The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary International Journal of Surgical Pathology, April 1, 2005; 13(2): 143 - 153. [Abstract] [PDF]

				B. W. G. van Rhijn, T. H. van der Kwast, A. N. Vis, W. J. Kirkels, E. R. Boeve, A. C. Jobsis, and E. C. Zwarthoff FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma Cancer Res., March 15, 2004; 64(6): 1911 - 1914. [Abstract] [Full Text] [PDF]

				P. J. Wild, A. Reichle, R. Andreesen, G. Rockelein, W. Dietmaier, J. Ruschoff, H. Blaszyk, F. Hofstadter, and A. Hartmann Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation Clin. Cancer Res., January 15, 2004; 10(2): 556 - 564. [Abstract] [Full Text] [PDF]

				M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky Genome-Wide Genetic Characterization of Bladder Cancer: A Comparison of High-Density Single-Nucleotide Polymorphism Arrays and PCR-based Microsatellite Analysis Cancer Res., May 1, 2003; 63(9): 2216 - 2222. [Abstract] [Full Text] [PDF]

				R Montironi, A Lopez-Beltran, R Mazzucchelli, and D G Bostwick Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies J. Clin. Pathol., February 1, 2003; 56(2): 91 - 95. [Abstract] [Full Text] [PDF]

				J. Cheng, H. Huang, J. Pak, E. Shapiro, T.-T. Sun, C. Cordon-Cardo, F. M. Waldman, and X.-R. Wu Allelic Loss of p53 Gene Is Associated with Genesis and Maintenance, but not Invasion, of Mouse Carcinoma in Situ of the Bladder Cancer Res., January 1, 2003; 63(1): 179 - 185. [Abstract] [Full Text] [PDF]